Yin Wei Ho

465 total citations
8 papers, 369 citations indexed

About

Yin Wei Ho is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Yin Wei Ho has authored 8 papers receiving a total of 369 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Hematology, 5 papers in Genetics and 3 papers in Molecular Biology. Recurrent topics in Yin Wei Ho's work include Chronic Myeloid Leukemia Treatments (6 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Acute Myeloid Leukemia Research (3 papers). Yin Wei Ho is often cited by papers focused on Chronic Myeloid Leukemia Treatments (6 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Acute Myeloid Leukemia Research (3 papers). Yin Wei Ho collaborates with scholars based in United States, United Kingdom and Switzerland. Yin Wei Ho's co-authors include Ravi Bhatia, Allen Lin, Bin Zhang, Tessa L. Holyoake, Claudia S. Huettner, Qin Huang, Alan Hair, Takahiro Maeda, Ya‐Huei Kuo and Hongjun Liu and has published in prestigious journals such as Blood and Cancer Cell.

In The Last Decade

Yin Wei Ho

7 papers receiving 365 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yin Wei Ho United States 3 291 127 127 86 66 8 369
Mayuka Nakatake Japan 9 238 0.8× 246 1.9× 226 1.8× 49 0.6× 61 0.9× 14 431
Ema Anastasiadou United States 6 351 1.2× 254 2.0× 121 1.0× 53 0.6× 73 1.1× 7 500
Jiřı́ Schwarz Czechia 11 245 0.8× 220 1.7× 249 2.0× 47 0.5× 31 0.5× 36 403
Edward Kavalerchik United States 6 244 0.8× 188 1.5× 142 1.1× 25 0.3× 125 1.9× 17 358
Hajime Akada United States 7 266 0.9× 244 1.9× 331 2.6× 46 0.5× 53 0.8× 12 437
Ruth Schwab Germany 4 300 1.0× 163 1.3× 132 1.0× 39 0.5× 103 1.6× 4 380
Megan Hatlen United States 7 166 0.6× 370 2.9× 115 0.9× 28 0.3× 51 0.8× 12 459
Sabrina Pechtel Germany 9 216 0.7× 102 0.8× 81 0.6× 27 0.3× 72 1.1× 12 292
Julia Romani Germany 9 150 0.5× 181 1.4× 102 0.8× 32 0.4× 67 1.0× 11 333
Jason G. Harb United States 12 245 0.8× 385 3.0× 168 1.3× 74 0.9× 60 0.9× 30 570

Countries citing papers authored by Yin Wei Ho

Since Specialization
Citations

This map shows the geographic impact of Yin Wei Ho's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yin Wei Ho with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yin Wei Ho more than expected).

Fields of papers citing papers by Yin Wei Ho

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yin Wei Ho. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yin Wei Ho. The network helps show where Yin Wei Ho may publish in the future.

Co-authorship network of co-authors of Yin Wei Ho

This figure shows the co-authorship network connecting the top 25 collaborators of Yin Wei Ho. A scholar is included among the top collaborators of Yin Wei Ho based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yin Wei Ho. Yin Wei Ho is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

8 of 8 papers shown
1.
Zhang, Bin, Yin Wei Ho, Tessa L. Holyoake, & Ravi Bhatia. (2013). Inhibition Of Microenvironmental Interleukin-1 Signaling Enhances TKI-Mediated Targeting Of Chronic Myelogenous Leukemia Stem Cells. Blood. 122(21). 512–512. 2 indexed citations
2.
Santos, Cédric Dos, Tinisha McDonald, Yin Wei Ho, et al.. (2013). The Src and c-Kit kinase inhibitor dasatinib enhances p53-mediated targeting of human acute myeloid leukemia stem cells by chemotherapeutic agents. Blood. 122(11). 1900–1913. 79 indexed citations
3.
Zhang, Bin, Yin Wei Ho, Qin Huang, et al.. (2012). Altered Microenvironmental Regulation of Leukemic and Normal Stem Cells in Chronic Myelogenous Leukemia. Cancer Cell. 21(4). 577–592. 271 indexed citations
4.
Li, Ling, Lisheng Wang, Liang Li, et al.. (2011). Pharmacological Inhibition of the Stress-Related Deacetylase SIRT1 Enhances Eradication of CML stem Cells. Blood. 118(21). 448–448.
5.
Zhang, Bin, Yin Wei Ho, Qin Huang, Claudia S. Huettner, & Ravi Bhatia. (2010). Altered Niche Interactions of Leukemia Stem Cells In a Chronic Phase Chronic Myelogenous Leukemia (CML) Transgenic Mouse Model.. Blood. 116(21). 1212–1212. 1 indexed citations
6.
Zhang, Bin, David Irvine, Yin Wei Ho, et al.. (2010). Inhibition of Chronic Myeloid Leukemia Stem Cells by the Combination of the Hedgehog Pathway Inhibitor LDE225 with Nilotinib. Blood. 116(21). 514–514. 14 indexed citations
7.
Zhang, Bin, Adam C. Strauss, Su Chu, et al.. (2009). Effective Targeting of Quiescent CML Stem Cells by Histone Deacetylase Inhibitors in Combination with Imatinib Mesylate.. Blood. 114(22). 190–190. 1 indexed citations
8.
Zhang, Bin, Yin Wei Ho, Sung‐Uk Lee, et al.. (2009). Characterization of Leukemia-Initiating Cells in a Transgenic Model of Chronic Phase Chronic Myelogenous Leukemia (CML).. Blood. 114(22). 858–858. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026